INTERACTION OF INTRAVENOUS DILTIAZEM WITH LOVASTATIN

这项研究将评估一种常用的钙拮抗剂，即地尔硫卓，已知具有阻断细胞色素P450 3A4的能力，并且我们之前的研究表明，口服时会导致药物与洛伐他汀的相互作用，在非肠道给药时是否会产生同样的相互作用。该方案将评估洛伐他汀是否易受药物动力学相互作用的影响，当静脉给予地尔硫卓时，这些相互作用会影响活性部分的形成。这项研究的具体目的是确定观察到的地尔硫卓与洛伐他汀的相互作用是发生在肠道还是在肝脏。静脉注射地尔硫卓将通过绕过肠道细胞色素P450 3A4来帮助回答这个问题。

This study will assess whether or not a commonly used calcium antagonist, namely diltiazem, that is known to have the capacity to block cytochrome P450 3A4, and which has been shown in our previous study to result in a drug interaction with lovastatin when given orally will produce the same interaction when given by the parenteral route. The protocol will evaluate whether lovastatin is susceptible to pharmacokinetic interactions that effect the formation of active moieties when diltiazem is given intravenously. The specific aim of the study is to determine whether the observed interaction of diltiazem with lovastatin, occurs at the intestinal level or in the liver. Intravenous therapy with diltiazem will help answer this question by bypassing the intestinal cytochrome P450 3A4.